Physician profile
Thuy Vo
NPI 1649649443
$990.79
in general payments reported to CMS, 2019-2025
14 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $106 · 2022: $201 · 2023: $227 · 2024: $318 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $684.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.71 | 2021-2024 | Jardiance, Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $144.85 | 2022-2023 | |
| Lexicon Pharmaceuticals, INC. | $118.71 | 2024 | Inpefa |
| Abbvie INC. | $105.64 | 2021-2024 | |
| Novo Nordisk INC | $85.74 | 2024-2025 | Wegovy, Rybelsus |
| Lilly USA, LLC | $79.03 | 2022-2025 | Zepbound, Jardiance, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.72 | 2023-2024 | Xifaxan |
| Sumitomo Pharma America, INC. | $66.85 | 2025 | Gemtesa |
| Lundbeck LLC | $24.62 | 2023 | Rexulti |
| Pfizer INC. | $24.45 | 2024 | |
| Eisai INC. | $24.33 | 2021 | |
| Zealand Pharma US, INC. | $17.81 | 2021 | |
| Genentech USA, INC. | $16.38 | 2021 | |
| Vertical Pharmaceuticals, LLC | $14.95 | 2023 | Dsuvia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thuy Vo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.